OPKO HEALTH, INC. OPK
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-0.79
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $606.9M | -$225.7M | $205.9M | — | $1.3B |
| 2024 | $713.1M | -$53.2M | $218.5M | — | $1.4B |
| 2023 | $863.5M | -$188.9M | $318.1M | — | $1.4B |
| 2022 | $1.0B | -$328.4M | $288.2M | — | $1.6B |
| 2021 | $1.8B | -$30.1M | — | — | $1.7B |
| 2020 | $1.4B | $30.6M | — | — | $1.7B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| PAGANELLI JOHN A | director | 2026-03-20 | Buy | 10,000 | $1.14 |
| FROST PHILLIP MD ET AL | CEO & Chairman | 2025-11-21 | Buy | 102,371 | $1.30 |
| FROST PHILLIP MD ET AL | CEO & Chairman | 2025-11-21 | Buy | 3,894 | $1.32 |
| FROST PHILLIP MD ET AL | CEO & Chairman | 2025-11-21 | Buy | 89,375 | $1.32 |
| FROST PHILLIP MD ET AL | CEO & Chairman | 2025-11-21 | Buy | 191,490 | $1.33 |
| FROST PHILLIP MD ET AL | CEO & Chairman | 2025-11-21 | Buy | 192,870 | $1.33 |
| FROST PHILLIP MD ET AL | CEO & Chairman | 2025-11-20 | Buy | 119,129 | $1.32 |
| FROST PHILLIP MD ET AL | CEO & Chairman | 2025-11-20 | Buy | 47,105 | $1.32 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.79 (distress)
- Working capital / assets 0.225
- Retained earnings / assets -1.186
- EBIT / assets -0.061
- Equity / liabilities 1.91
Source: SEC EDGAR filings · CIK 0000944809 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.